Coegin Pharma merges with Follicum
Coegin Pharma has announced successfully completing the merger acquisition of Lund-based diabetes company Follicum. The company, currently conducting a phase I/II trial with lead candidate AVX001 in actinic keratosis and preclinical development of AVX420 in leukemia...
BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB
BerGenBio announces the the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for bemcentinib in combination with and anti-PD-(L)1 agent for the treatment of patients with AXL-positive advanced/metastatic non-small cell lung cancer (NSCLC)...
APIM THERAPEUTICS COMPLETES PRIVATE PLACEMENT AND ENTERS PHASE-2
APIM Therapeutics today announces the completion of a private placement directed towards existing and certain new investors in the Company. The proceeds from the investment round will be used to conduct a Phase-2 study in sarcoma. The study will be initiated and...
APIM Therapeutics announces IND for ATX-101 in Ovarian Cancer
APIM Therapeutics AS announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phase 1b/2a clinical trial to investigate ATX-101 in combination with platinum-based therapy in ovarian cancer. The trial...
Arxx Therapeutics Secures NOK110
APIM Therapeutics AS announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phase 1b/2a clinical trial to investigate ATX-101 in combination with platinum-based therapy in ovarian cancer. The trial...
Heimdall Power raises NOK 155 mill
The Norwegian Investment Company Saga Pure ASA has entered into an agreement to invest NOK 75 mill into Sarsia Seed portfolio company Heimdall Power AS to help accelerate the company's growth strategy. The total transaction was 155mNOK involving existing investors...
Coegin Pharma AB listed on Nordic SME
Sarsia Seed portfolio company Coegin Pharma AB was yesterday listed on Nordic SME stock exchange. (Ticker: COEGIN) Read more
Vaccibody AS Lists on Oslo Stock Exchange
Sarsia Seed portfolio company Vaccibody AS - was today listed on Oslo Stock Exchange´s Merkur Markets list. ...
Vaccibody enters into worldwide license and collaboration agreement with Genentech
It was announced today that Sarsia Seed portfolio company Vaccibody AS enters into $715m lisence and collaboration agreement with Genentech.Low double-digit tiered royalties on sales of commercialized products arising from the partnership are in addition. ...
Vaccibody and Nektar Therapeutics Announce First Patient Dosed in collaborative Phase 1/2a Study
Vaccibody AS and Nektar Therapeutics (NASDAQ: NKTR) announce that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin (bempeg), Nektar’s CD122-preferential IL-2 pathway agonist, with VB10.NEO, Vaccibody's...